Mimedx Group Inc (MDXG) Exchange: NASDAQ

Mimedx Group, Inc. (MDXG) is a biopharmaceutical company based out of Marietta, Georgia. Founded in 2007 by Dr. Bill Taylor, a three-time recipient of the Medical Design Excellence Award, MDXG develops, manufactures and markets regenerative biologics to healthcare providers and researchers across the world. MDXG has grown over the years, developing numerous patented and or license-protected products for use in general and specialty surgery settings, including a range of products in the area of amniotic tissue. MDXG’s products can be found in more than 20 countries and the company has over 500 employees. Through strategic acquisitions and partnerships with leading companies, MDXG has created a suite of products that account for around half of its current revenue. In recent years, the company has also seen a significant increase in its product sales, with US intravenous therapy revenue increasing by 70% year-over-year in 2019. The company has also seen sustained growth in its product portfolio, launching 19 new and expanded products in the first six months of 2020. By leveraging its ability to quickly develop and deploy an innovative product pipeline, MDXG hopes to continue its upward trajectory and expand its presence both domestically and internationally. In addition to its focus on regenerative medicine, MDXG is currently working to develop breakthrough technologies for other areas of medicine, including cardiopulmonary and wound healing. Ultimately, MDXG seeks to bridge the gap between cutting-edge research, cardiovascular science and industry expertise to advance treatments for patients around the world.